1. Indonesia Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
PT Indofarma Tbk

PT Indofarma Tbk

INAF.JK
PT Indofarma TbkID flagIndonesia Stock Exchange
126.00
IDR
- -
- -
390.51BMarket Cap

Total Valuation

PT Indofarma Tbk carries a market capitalization of 390.51B, placing it among publicly traded companies globally. Its enterprise value stands at 694.60B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap390.51B
Enterprise Value694.60B

Share Statistics

PT Indofarma Tbk currently has 3.10B shares outstanding.

Shares Outstanding3.10B
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Enterprise Valuation

EV / Sales4.58
EV / EBITDAN/A
EV / EBITN/A
EV / FCF20.91

Financial Position

PT Indofarma Tbk maintains a current ratio of 0.19, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -99.06, indicating conservative leverage, while an interest coverage ratio of -6.84 demonstrates limited ability to service its debt obligations.

Current Ratio0.19
Quick Ratio0.01
Debt / Equity-99.06
Debt / EBITDA-3.36
Interest Coverage-6.84

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-13.52
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover3.45

Taxes

Income Tax6.53B
Effective Tax RateN/A

Stock Price Statistics

PT Indofarma Tbk's stock has declined approximately -80.46512% over the past 52 weeks. The 50-day moving average sits at 126.00, while the 200-day moving average is 138.02.

Beta (5Y)N/A
52-Week Price Change-80.46512%
50-Day Moving Average126.00
200-Day Moving Average138.02
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, PT Indofarma Tbk generated 151.55B in revenue and converted that into -77.99B in net income, yielding earnings per share of -25.16. EBITDA reached -208.22B, while operating income came in at -208.22B.

Revenue151.55B
Gross Profit-19.22B
Operating Income-208.22B
Pretax Income-71.46B
Net Income-77.99B
EBITDA-208.22B
EBIT-208.22B
Earnings Per Share (EPS)-25.16

Balance Sheet

PT Indofarma Tbk holds 5.69B in cash and equivalents against 700.28B in total debt, resulting in a net debt position of 694.60B. Total book value stands at -1.12T, with working capital of -513.42B providing operational flexibility.

Cash & Cash Equivalents5.69B
Total Debt700.28B
Net Debt694.60B
Equity (Book Value)-1.12T
Book Value Per Share-362.97
Working Capital-513.42B

Margins

PT Indofarma Tbk operates with a gross margin of -12.68, reflecting its pricing power and cost economics. The operating margin of -137.39 and net profit margin of -51.46 provide insight into operational efficiency.

Gross Margin-12.68
Operating Margin-137.39
Pretax Margin-47.15
Profit Margin-51.46
EBITDA Margin-137.39

Scores

PT Indofarma Tbk posts an Altman Z-Score of -5.92, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-5.92